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Abstract
Benzophenone-3 (BP-3), the most widely used UV chemical filter, is absorbed well through the skin and gastrointestinal tract and
can affect some body functions, including the survival of nerve cells. Previously, we showed that BP-3 evoked a neurotoxic effect
in male rats, but since the effects of this compound are known to depend on gender, the aim of the present study was to show the
concentration and potential neurotoxic action of this compound in the female rat brain. BP-3 was administered dermally to female
rats during pregnancy, and then in the 7th and 8th weeks of age to their female offspring. The effect of BP-3 exposure on short-
term and spatial memory, its concentrations in blood, the liver, the frontal cortex, and the hippocampus, and the effect on selected
markers of brain damage were determined. Also, the impact of BP-3 on sex and thyroid hormone levels in blood and hemato-
logical parameters was examined. It has been found that this compound was present in blood and brain structures in females at a
lower concentration than in males. BP-3 in both examined brain structures increased extracellular glutamate concentration and
enhanced lipid peroxidation, but did not induce the apoptotic process. The tested compound also evoked hyperthyroidism and
decreased the blood progesterone level and the number of erythrocytes. The presented data indicated that, after the same exposure
to BP-3, this compound was at a lower concentration in the female brain than in that of the males. Although BP-3 did not induce
apoptosis in the hippocampus and frontal cortex, the increased extracellular glutamate concentration and lipid peroxidation, as
well as impaired spatial memory, suggested that this compound also had adverse effects in the female brain yet was weaker than
in males. In contrast to the weaker effects of the BP-3 on females than the brain of males, this compound affected the endocrine
system and evoked a disturbance in hematological parameters more strongly than in male rats.




3) is the most widely used UV-absorbing compound. This
compound is included not only in sunscreen formulas but also
in most other cosmetics and is used as a stabilizer in plastic
food packaging materials. BP-3 absorbs well through the skin
from preparations containing it, and also from the gastrointes-
tinal tract from contaminated food or water (Janjua et al.
2004). This compound is considered to be a pollutant of the
water reservoir environment, accumulates in aquatic organ-
isms, and, at a high concentration, is found in fish fat (Fent
et al. 2010). In people, BP-3 is absorbed well through the skin
and is detected in serum in concentrations ten times higher
than other chemical filters, plus the presence of its metabolites
has been demonstrated in about 98% of urine samples (Calafat
et al. 2008; Janjua et al. 2008; Tarazona et al. 2013).
Benzophenones belong to the group of endocrine-
disrupting chemicals (EDCs) and affect the function of sex
and thyroid hormones. So far, the effects of BP-3 on estrogen
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receptors (ER) have been studied best, and both in vivo and
in vitro studies indicate the agonistic effect of this compound
on the ER. It was also found that BP-3 exhibited an antago-
nistic effect on the human androgen receptor (AR) and pro-
gesterone receptors (PR) and may contribute to fertility reduc-
tion in both women and men, and in the development of
hormone-dependent tumors (Ma et al. 2003; Schlumpf et al.
2001, 2004; Schreurs et al. 2005).
In contrast to the relatively well-characterized BP-3 action
on the function of the gonads, little data relates to the action of
this compound on brain cells. When considering the increasing
exposure of people to this compound, the possibility of its in-
terfering with the central effects of steroid and thyroid hor-
mones, and data indicating that compounds from the EDCs
group may damage neurons, BP-3 may prove to be an impor-
tant factor involved in the induction or intensification of cell
damage observed in neurodegenerative diseases. So far, the
neuron-damaging effects of BP-3 were demonstrated in vitro
(Broniowska et al. 2016; Wnuk et al. 2018a), in vivo in the
brains of mice embryos after prenatal exposure (Wnuk et al.
2018b, 2019), and in our studies in adult male rats after com-
bined prenatal and adult dermal exposure (Krzyżanowska et al.
2018; Pomierny et al. 2019).In our previous studies, dermal
administration of BP-3 in both the prenatal period, when the
brain cells are the most sensitive to neurotoxic factors, and for
2 weeks to adult male rats, we showed pro-apoptotic changes in
the frontal cortex and CA1 region of the hippocampus, and
most likely this action was related to elevated levels of extra-
cellular glutamate (Krzyżanowska et al. 2018; Pomierny et al.
2019). Because it was found that after dermal exposure to BP-3,
with higher concentrations of this compound in human beings
found in the blood of males than females, it seems that the
neuronal damaging effects of BP-3 may also be dependent on
gender (Janjua et al. 2008). Therefore, the aim of the present
study was to show whether, after the same exposure to BP-3 as
previously used in the case of males, there are differences in
female rats in the concentration of this compound in the blood,
in its level in the brain, and in the damage to brain cells. In order
to determine the mechanism of BP-3 action in the central ner-
vous system of female rats, its effect on factors involved in
neuronal damage or protection processes, such as (1) increase
in extracellular glutamate concentrations and expression of its
transporters, (2) activation of microglial cells, (3) lipid peroxi-
dation intensification, (4) expression of sex hormone receptors
mediating the neuroprotective hormones’ effect, and (5) the
level of the arylhydrocarbon receptor (AhR) involved in the
neurodegenerative activity of many EDCs was investigated in
the frontal cortex and hippocampus. These brain structures
were selected because they are most vulnerable to damage
and have key involvement in the cognitive processes.
Moreover, to assess memory deficits, short-term and spatial
memory was determined in a new object and new location
recognition test. In the current study, BP-3 was administered
dermally due to this being the main route of exposure in
humans. This compound was applied in the prenatal period
and during the first 2 weeks of adulthood because, firstly, we
wanted to compare its effects in females with previously tested
effects in males and, secondly, this pattern of administration is
the best way to observe the brain cell damage. A lot of current
research indicates that exposure to xenobiotics in the prenatal
period sensitizes brain cells and leads to stronger damaging
effects of this compound acting later in life (Li et al. 2014;
Lien et al. 2015; Modgil et al. 2014).
Endocrine-disrupting chemicals, including UV filters from
the benzophenone group, in addition to the effects on the sex
hormones, most often also disturb the function of the thyroid
gland (Broniowska et al. 2018; Hofmann et al. 2009). In the
case of sex hormones, EDCs usually affect the function of their
receptors without changing the level of the hormones them-
selves, while in the case of thyroid hormones, these compounds
rather interfere with their synthesis. To determine the effect of
BP-3 on gonadal hormone, blood concentrations of 17β-estra-
diol, progesterone, and testosterone were determined. Since
prolactin by inhibition of gonadotropins is a common cause
of low sex hormone levels, its concentration was also deter-
mined. To determine the activity of the hypothalamic-
pituitary-thyroid (HPT) axis, the concentrations of free fractions
of triiodothyronine (fT3) and thyroxin (fT4), and the thyroid-
stimulating hormone (TSH), were determined. Free hormone
fractions were assayed, because their blood levels better reflect
the thyroid function than the total of T3 and T4.
To date, there is no evidence on the impact of BP-3 on the
number and morphology of blood cells. However, one benzo-
phenone derivative from the fruit ofGarcinia indica (garcinol)
has been shown to affect the membrane of human erythrocytes
and causes cell shrinkage (Fazio et al. 2015). Previously, we
found that another benzophenone derivative, benzophenone-
2, neither changed the leukocyte, erythrocyte, or platelet count
nor affected the morphology and hemoglobin content in eryth-
rocytes, although this compound was administered to adult,
male rats and additionally exhibits less cytotoxic activity than
BP-3 (Broniowska et al. 2018). Therefore, the next aim of this
study was to evaluate the effects of BP-3 on the hematological
parameters of peripheral blood in female rats. We determined
the red blood cell (RBC) count, mean corpuscular volume
(MCV), hematocrit (HCT), hemoglobin concentration
(HGB), mean cell hemoglobin concentration (MCHC), leuko-
cyte count (WBC), and platelet count (PLT).
Materials and Methods
Animals and Treatment
The experiments were performed on Sprague Dawley rats
from the animal housing facility of the Jagiellonian
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UniversityMedical College in Cracow. The animals were kept
under a natural day-night cycle at 22 ± 2 °C with food and
water available at libitum.
To determine estrous cycle phases, vaginal smears were
taken from the females on a daily basis. On the proestrus
day, the females were placed with males for 12 h, and the
vaginal smears were subsequently examined for the presence
of sperm.
BP-3 (purity-98%) obtained from Merck (Darmstadt,
Germany) was formulated daily in Essex cream (Schering-
Plough, Brussels, Belgium) at a final concentration of 10%,
and administered from the first to the last day of pregnancy
(approx. 22–23 days). Prior to treatment, the hair on the back
of the neck to halfway towards the tail region was shaved and
the animals were reshaved during treatment when the hair
began to reappear. The examined group was treated with
cream containing BP-3, at a dose of 100 mg/kg twice daily
(at 8:00 and 17:00), whereas control female rats were treated
with Essex cream without BP-3.We used a dose of 100 mg/kg
BP-3, because after this dose, BP-3 blood levels in rats are
comparable to those seen in humans using preparations con-
taining this compound. It was shown that in humans after
dermal application of a formulation containing 5% BP-3, the
maximum concentration of these compound in plasma was
200–300 μg/l, and after 24 h about 80–200 μg/l (Tarazona
et al., 2013). Similarly, Janjua et al. (2008) found that after a
single application of BP-3, its concentration in the serum in
men was about 250 ng/ml. We observed comparable BP-3
blood levels in the male rat, i.e. 216 ng/ml after the 100-mg/kg
dose (Pomierny et al., 2019). After birth, the offspring were
kept with the dam without any treatment. Twenty-one days
after birth, male and female offspring were weaned and
housed in groups of five per cage (with the males and females
being separated) under standard conditions, without any treat-
ment until the 43rd day. From 43 to 56 days of age, the female
rats whose mothers received BP-3 were administered
dermally with this compound, whereas cream without BP-3
was given to the control animals. The animals were observed
daily for any abnormalities and their weights were recorded
weekly. Two hours after the last morning BP-3 (or vehicle)
application, the animals were subjected to the novel object
recognition test or the novel location of the object recognition
test. All tests were performed on 2-month-old females
weighing 227.4 ± 15,5 g (control group) and 230.3 ± 12.8 g
(BP-3 group). On the next day (24 h after the last BP-3 ad-
ministration), the animals were euthanized via rapid decapita-
tion. A small volume of the trunk blood was collected either in
heparinized tubes for the hematological determination or the
remaining volume in tubes containing EDTA, and these blood
samples were centrifuged at 800×g, at 4 °C for 15 min and
then plasma was stored at − 80 °C until used for biochemical
assays. The brains and livers were rapidly removed, and the
brain structures (hippocampus and frontal cortex) were
dissected on ice-cold glass plates, frozen on dry ice, and stored
at − 80 °C.
Novel Object and Novel Location Recognition Tests
To determine the impact of BP-3 on cognitive function (short-
term and spatial memory), female rats from control and BP-3-
treated groups were subjected to a novel object or novel loca-
tion recognition test (Jabłoński et al. 2013). During habitua-
tion, the animals were allowed to explore an empty container
and 24 h later they were exposed for 5 min to the same area
containing two identical objects placed at an equal distance.
Next, the animals were subdivided into two groups and 1 h
after the pretest, rats from the first group were allowed to
explore the same container for 5 min in the presence of the
familiar object and a novel object, consistent in height and
volume but different in shape and appearance. Animals from
the second group were placed in the same container equipped
with two identical familiar objects, but one of them was locat-
ed in another place. The tests were recorded. After the tests
were conducted, the films were manually checked to calculate
the time that the animals spent exploring both objects. The
results of the tests were presented as the preference index,
i.e., the ratio of the time the animal spent exploring a novel
object (for the novel object test) or exploring the object located
in another place (for the novel location test) to the time spent
exploring of both object.
LC/MS Analysis of BP-3
Tissues were homogenized in deionized water. Samples of
homogenate or plasma mixed with internal standard were sub-
jected to extraction by adding heptane and dichloromethane
(1:1; v/v) and shaking for 10 min on an oscillating shaker.
After centrifugation (10 min at 4000×g), the organic layer
was obtained and evaporated under nitrogen stream at 37 °C.
Next, the chromatographic separation with mass spectro-
metric analysis was performed using Agilent 1100 liquid chro-
matograph (Agilent, Waldbronn, Germany) coupled to a mass
spectrometer API 2000 (triple quadrupole) (Applied
Biosystems MDS Sciex, Concord, Ontario, Canada) equipped
with an elect rospray ionizat ion (ESI) interface.
Chromatography equipment included a degasser, a binary
pump, an autosampler and a column (Thermo Scientific
BDS Hypersil C18; 100 × 3 mm I.D., 3 μm particle size)
thermostated at 30 °C with its precolumn (100 × 3 mm I.D.,
3 μm particle size) was used to separate samples—the volume
of the sample injection was 40 μl with the flow rate of 0.4 ml/
min. The mobile phase compositions were 0.025% glacial
acetic acid in water (A) and methanol (B) with gradient: 0–
1.5 min, isocratic gradient 40.0% (B); 1.5–2,5 min, linear
gradient 40.0–95.0% (B); 2.5–6,5 min, isocratic gradient
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95.0% (B); 6.5–8,0 min, linear gradient 95.0–40.0% (B); 8.0–
10.0 min, and isocratic gradient 40.0% (B).
High-purity nitrogen (99.9%) from Peak NM20ZA as a
curtain and collision gas and electrospray ionization in posi-
tive mode were used in the mass spectrometry analysis. The
following parameters of ion source were applied: ion spray
voltage (IS) 5000 V; nebulizer gas (gas 1) 20 psi; turbo gas
(gas 2): 10 psi; temperature of the heated nebulizer (TEM)
250 °C; curtain gas (CUR) 20 psi, and the next ion path pa-
rameters for BP-3, BP-1, and BP-d10 were declustering po-
tential (DP) 8 V; focusing potential (FP) 10 V; collision cell
entrance potential (CEP) 13 V; and collision cell exit potential
(CXP) 18 V. The following pairs of ions were monitored
(values of m/z in brackets): BP-3 (229.0/151.1), BP-1
(215.0/107.0), and BP-d10 (193.0/110.0). For data analysis,
Analyst software 1.6 (Perlan Technologies) was used. BP-3
and BP-1 concentrations were computed using calibration
curves, constructed by linear regression analysis of the peak
area versus concentrations.
Total Antioxidant Capacity
The total antioxidant capacity was determined using a modi-
fication of the ORAC method previously described by Sofic
et al. (2002) and Prior and Cao (1999). Within this assay, the
loss of fluorescein (as a probe) fluorescence is measured over
time due to peroxyl-radical formation by the breakdown of
2,2′-azobis-2-methyl-propanimidamide dihydrochloride
(AAPH). The tissue antioxidants inhibit this reaction. 6-
Hydroxsy-2,5,7,8-tetramethylchroman-2-carboxylic acid
(TROLOX) was used as a standard in the concentration range
from 2.5 to 200 μM. The results were calculated according to
Prior and Cao (1999), using the differences in areas under the
fluorescein decay curves between the blank and a sample, and
extrapolated to the TROLOX standard curve prepared in the
same manner. Data are expressed as a percentage of the con-
trol group.
Lipid Peroxidation (MDA) Level
Fluorimetric assays for lipid peroxidation were performed
using the Lipid Peroxidation (MDA) Colorimetric/
Fluorometric Assays Kit (BioVision, USA). The assay is
based on the reaction of the main product of lipid peroxida-
tion, malondialdehyde (MDA) with thiobarbituric acid
(TBA), at 95 °C for 60 min. The product of this reaction is
MDA-TBA adduct, which can be quantified fluorometrically
(Ex/Em = 532/553). The fluorescence was measured by a
fluorescence plate reader (Fluoroskan Ascent FL, Thermo
Labsystems). Lipid peroxidation in the samples was calculat-
ed from the standard curve and gathered as nanomoles of
MDA per milligram of protein. The results were recalculated
and expressed as a percentage of the control group.
Microdialysis of Frontal Cortex and Hippocampus
After 2.5% isoflurane anesthesia guide cannulas were stereo-
taxically implanted in the animals’ frontal cortex
(anteroposterior (AP) −0.48 mm; mediolateral (ML)
+2.0 mm; dorsoventral (DV) −1,2 mm—according to the atlas
of Paxinos and Watson (2007), and the hippocampus (AP
−4.36 mm; ML +1.8 mm; DV −2.5 mm)) using dental acrylic
cement and cranial screws. Next, the cannulas were supported
with obturators and 24 h later microdialysis was performed.
Afterwards, the obturators were removed and, before
collecting the first baseline sample, microdialysis probes
(MAB 4, membrane with a molecular weight of 6 kDa cutoff,
2 mm length and 0.24 mm outer diameter, AgnTho’s AB,
Sweden) were perfused with artificial cerebrospinal fluid
(aCSF components [mM]: NaCl 147, KCl 4.0, MgCl2 1.0,
CaCl2 2.2, pH 7.4) for 2 h at a constant flow rate of 2 μl per
minute. Then, microdialysis probes were inserted into the
guide cannulas of the frontal cortex and hippocampus before
microdialysis samples were collected every 30 min for 3 h and
immediately frozen and kept at a temperature of − 80 °C until
further chromatographic analysis.
LC-MS Analysis of Glu
The chromatographic separation with mass spectrometric
analysis was performed using the Agilent HPLC 1100 series
system (Agilent, Waldbronn, Germany). Chromatographic
separation parameters were based on Jastrzębska et al.
(2015). Chromatography equipment included a degasser, a
binary pump, an autosampler, and a thermostated column
compartment. LiChrospher 60RP-select B column (125mm×
4.6 mm ID, 5 μm particle size) and a suitable guard column
(4 mm× 4 mm, 5 μm particle size) (Merck, Germany) were
used to separate aCSF samples. Following this, pairs of ions
were monitored (values of m/z in brackets): Glu (148.0/84.1),
Glu-d5 (153.22/89.1). For data analysis, Analyst software 1.4
(AB SCIEX, USA) was used. Glu concentrations in the noted
brain structures were computed using calibration curves, con-
structed by linear regression analysis of the peak area versus
concentrations. The presented data are expressed as the means
of six samples collected every 30 min during 3 h of microdi-
alysis for each animal.
RT-PCR Method
The female rats were decapitated 24 h after the last BP-3
administration; their brains were immediately removed, and
the hippocampus and frontal cortex were isolated and im-
mersed in RNAlater solution (Ambion, USA). According to
the manufacturer’s protocol, the total RNA was extracted
using TRI Reagent (Zymo Research, USA) and purified with
Direct-zol RNA Miniprep Kit (Zymo Research, USA).
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Reverse transcription reactions and real-time PCR were con-
ducted using a Transcriptor First Strand cDNA Synthesis kit
and Fast Start Universal Probe Master (ROX) (Roche,
Germany). According to the manufacturer’s protocol and
using the PrimeQ real-time PCR system expression of the
GLT-1, xc−, ERα, ERβ, GPR-30, AhR, C1qb, Cd40, Aif,
and the reference gene GAPDH was analyzed. The fold
change in expression was determined using theΔΔc(t) meth-
od of relative quantification.
Western Blot Analysis
To obtain the membrane, nucleus, cytosol, and cytoskele-
ton fractions, the frontal cortex and hippocampus were
subjected to subcel lular fract ionat ion using the
Subcellular Protein Fractionation Kit (Roche, Germany).
The protein concentrations were determined by the BCA
Protein Assay Kit (Thermo, USA), and the individual cell
fractions after dilution to the same protein concentration
were mixed with a loading buffer (1:1) and heated for
5 min at 95 °C. Afterwards, samples containing 30–
50 μg of the total protein in 15 μl were loaded on the
stain-free gradient 4–15% SDS polyacrylamide gels (Bio-
Rad, USA) and the electrophoresis was performed for 1 H
at 150 V. The total amount of protein was evaluated in
gels using the G:BOX Imaging System (Syngene, USA).
Then, the proteins were transferred to PVDF membranes
using a Trans-Blot Turbo Transfer System (Bio-Rad,
USA). After several washes and blocking non-specific
binding sites in 5% BSA, the membranes were incubated
overnight with the following primary antibodies (in 1%
BSA): anti-GLT-1 (EAAT2), anti-xc−, anti-ERα, anti-
ERβ, anti-GPR30, anti-PR, anti-AhR, anti-Caspase 3 ac-
tive, anti-Caspase 8, anti- Caspase 9, anti-Bax, anti-Bcl-2,
anti-Iba1, anti-Caspase-1, anti-RIP, anti-glutathione (GPx)
(Abcam (UK) or Santa Cruz Biotechnology (USA)). The
membranes were then washed several times and incubated
for 1 H at room temperature with proper secondary anti-
bodies (in 1% BSA): goat anti-mouse-HRP, 1:7500,
sc2005, Santa Cruz Biotechnology (USA); and goat anti-
rabbit-HRP, 1:10000, ab6721, Abcam (UK) (Table 1).
After washing, the signals were developed using the
ECL method (Western Bright Quantum, Advansta, USA)
and acquired by the G:BOX Imaging System (Syngene,
USA). Making use of Gene Tools software (Syngene,
USA), the protein expression was analyzed, taking into
account the total amount of protein loaded into each well.
Immunofluorescence Staining
For immunofluorescence staining, a separate group of animals
was used and these animals were subjected to intracardiac
perfusion for 24 h following the last administration of BP-3
or the vehicle. In order to do this, deep anesthesia was induced
with ketamine (80 mg/kg) and xylazine (20 mg/kg). The rats
were transcardially perfused with 250 ml of saline (0.9%
NaCl, 32 °C) until all of the remaining blood was removed.
Next, the animals were perfused with 500 ml of cold (4 °C)
4% PFA in 0.1M phosphate-buffered saline (PBS). The brains
were removed and immersed in the same 4% PFA solution
overnight. At the start of the following day, the brains were
immersed in sucrose solutions in 0.1 M PBS (concentration
gradient 10%, 20%, and 30%) until they sank and stored (−
80 °C) until sectioning. The tissues were cut into coronal
20-μm sections using an automatic cryostat (Leica CM1860,
Germany) and placed on microscopic slides. The slides were
stored at − 20 °C until staining.
Immunostaining procedure: For active caspase-3 stain-
ing, trisodium citrate buffer solution (pH ≈ 9) was used as
an antigen retriever buffer. The antigen retrieval was car-
ried out in glass containers in a water bath for 30 min at
80 °C. Next, the containers were removed from the water
bath and allowed to return to room temperature. All of the
sections were washed twice in 0.2% Tween in PBS solu-
tion (PBST). Depending on the combination of secondary
antibodies, 10% donkey normal serum (DNS) or 10% don-
key and goat normal serum (1:1) (DNS + GNS) solution in
PBSTwas used to block nonspecific antibody binding. The
tissues were incubated in blocking medium for 1 h at room
temperature. Next, the blocking medium was removed, and
the tissues were immersed in appropriate primary antibody
solutions (anti-Caspase 3 active, 1:300, ab2302, Abcam
(UK)). The tissues were double-stained together with a
neuronal marker (anti-MAP2, 1:1000, ab5392, Abcam
(UK)), astroglial marker (anti-GFAP, 1:1000, ab4674,
Abcam (UK)) or microglial marker (anti-Iba1, 1:200,
ab5076, Abcam (UK)). Each mixture of two specific anti-
bodies was dissolved in an appropriate 2% DNS or DNS +
GNS serum in PBST. The slides were incubated with pri-
mary antibody solutions at 4 °C overnight. The following
day, the slides were removed and incubated for 1 h on a
shaker at room temperature. Next, the sections were
washed twice in 2% DNS or DNS + GNS in PBST. The
tissues were immersed in appropriate secondary antibodies
(goat anti-chicken AF, 1:300, ab150173, Abcam (UK);
donkey anti-goat AF, 1:500, ab150133, Abcam (UK); and
donkey anti-rabbit TR, 1:300, ab6800, Abcam (UK)) solu-
tion in PBST and incubated for 1 h in the dark at room
temperature. The antibodies used are shown in Table 1.
Afterwards, the sections were washed three times in
PBST, dried, and mounted in Fluoroshield mounting me-
dium (Sigma, USA) and coverslipped. The staining was
visualized using a Leica DMI8 (Germany) fluorescence
inverted microscope. Images of motor-frontal cortex, as
well as CA1, CA3, and DG fields of the hippocampus,
were captured by a digital CCD camera (Leica DFC450,
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Germany) and expressed as the relative fluorescence unit
(RFU).
Measurement of GPx Activity
GPx activity was estimated using method described by
Lawrence and Burk (1976) based on the oxidation of
NADPH to NADP+. Briefly, frozen samples of hippocampus
were homogenized on ice and diluted in potassium sodium
phosphate buffer (pH = 7). The working solution added to
homogenates included NADPH, reduced glutathione (GSH),
sodium azide, EDTA, and glutathione reductase (GR).
Furthermore, hydrogen peroxide was used as a substrate,
whose degradation in the presence of GSH was proceeded.
GR catalyzed the NADPH-driven reduction of the generated
oxidized glutathione (GSSG) followed by NADP+ formation.
The decrease in samples’ absorbance proportional to the ac-
tivity of GPx was measured at 340 nm for 30 min at 37 °C by
multiwell plate reader POLARstar Omega (BMG Labtech,
Germany). Results were expressed relative to the total amount
of protein in samples using the BCA Protein Assay Kit
(Thermo, USA).
Determination of Blood Hormone Levels
The concentration of 17β-estradiol (ab108667; Abcam, UK),
progesterone (CSB-E07282r; Cusabio, China), testosterone
(ab108666; Abcam, UK), prolactin (CSB-E06881r; Cusabio,
China), fT3 (DKO037; DiaMetra, Italy), fT4 (DKO038;
DiaMetra, Italy), and thyroid-stimulating hormone (TSH;
CSB-E05115r; Cusabio, China) were determined using com-
mercial ELISA kits. The assays were performed using undi-
luted plasma according to the manufacturers’ manuals. The
absorbance was measured in a multiwell plate reader
(TECAN Infinite M200 PRO), and hormone concentrations
in the samples were calculated from a calibration curve.
Hematological Analyses
Immediately after collection, whole blood samples with heparin
were used for hematological analyses. The leukocyte count
Table 1 List of antibodies with
their concentrations and vendors
used in this study
Target molecule Dilution Catalog number Manufacturer
Western blot—primary antibodies
GLT-1 (EAAT2) 1:3000 ab41621 Abcam (UK)
xc− 1:2000 ab37185 Abcam (UK)
ERα 1:400 sc-787 Santa Cruz Biotechnology (USA)
ERβ 1:1000 ab3576 Abcam (UK)
GPR30 1:2000 ab39742 Abcam (UK)
AhR 1:200 sc-133,088 Santa Cruz Biotechnology (USA)
Caspase-3 active 1:1000 ab2302 Abcam (UK)
Caspase-8 active 1:400 sc-56,070 Santa Cruz Biotechnology (USA)
Caspase-9 1:400 sc-17,784 Santa Cruz Biotechnology (USA)
Bax 1:2000 ab32503 Abcam (UK)
Bcl-2 1:400 sc-7382 Santa Cruz Biotechnology (USA)
Caspase-1 1:500 ab179515 Abcam (UK)
RIP1 1:500 ab72139 Abcam (UK)
GPx 1:200 sc-22,145 Santa Cruz Biotechnology (USA)
Western blot—secondary antibodies
Goat anti-mouse-HRP 1:7500 sc-2005 Santa Cruz Biotechnology (USA)
Goat anti-rabbit-HRP 1:10000 ab6721 Abcam (UK)
Immunofluorescence staining—primary antibodies
MAP2 1:1000 ab5392 Abcam (UK)
GFAP 1:1000 ab4674 Abcam (UK)
Iba-1 1:200 ab5076 Abcam (UK)
Caspase-3 active 1:300 ab2302 Abcam (UK)
Immunofluorescence staining—secondary antibodies
Goat anti-chicken AF 1:300 ab150173 Abcam (UK)
Donkey anti-goat AF 1:500 ab150133 Abcam (UK)
Donkey anti-rabbit TR 1:300 ab6800 Abcam (UK)
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(WBC), red blood cell count (RBC), platelet count (PLT), he-
moglobin concentration (HGB), hematocrit (HCT), mean cor-
puscular volume (MCV), mean cell hemoglobin (MCH), and
mean cell hemoglobin concentration (MCHC) were analyzed
by means of a Cobas Micros (Roche, Palo Alto, CA, USA)
analyzer. Hematological analyses were systematically checked
as reported previously (Starek et al. 2008).
Statistical Analysis
All data were expressed as the means (±SEM—standard error
of the mean) and analyzed in a GraphPad Prism (version 6.0,
USA) program. Normal distribution of data sets was deter-
mined by a Shapiro-Wilk normality test, and t tests were used
in further statistical analysis. The p value below 0.05 was
considered statistically significant.
Results
The Effect of BP-3 on Short-Term and Spatial Memory
in Female Rats
The short-term and spatial memories were determined in a
new object and new location recognition test, respectively,
Fig. 1 Effects of BP-3 dermal administration to female rats on short-term
memory performance in a novel object recognition test (NOR) and spatial
memory performance in a novel object location test (NOL) (n = 7). The
results are expressed as the means of the preference index ± S.E.M. *
p < 0.05 vs control group; BP-3—benzophenone-3; C—control group
Fig. 2 Concentration of BP-3 in plasma (a); liver (b); frontal cortex (d); hippocampus (e), and BP-1 content in liver (c) (n = 6). All values are expressed
as the means ± S.E.M. **p < 0.01, ***p < 0.001, ****p < 0.0001 vs control group. BP-1—benzophenone-1; BP-3—benzophenone-3; C—control group
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and presented as the preference index (Fig. 1). Exposure of
female rats to BP-3 in prenatal and, next, at 2 weeks of adult-
hood had no effect on the short-term memory (p = 0.8127),
but significantly disturbed the spatial memory (p < 0.05).
Concentration of BP-3 in Plasma, Liver, and Brain
Structures and BP-1 in Liver in Female Rats
BP-3 levels were determined 24 h after the last administration
of this compound. In the plasma of all of the control animals,
the level of BP-3 was below the limit of detection, while in
animals exposed to this compound it was in the range of 70–
220 ng/ml (average 169 ng/ml) (Fig. 2a) (p < 0.001). In the
liver, a much higher level of the main BP-3 metabolite, BP-1
(156 ng/g wet tissue), was found, while the parent compound
occurred in 25 ng/g wet tissue concentration (Fig. 2b, c)
(p < 0.0001 and p < 0.0001). In BP-3-treated animals, this
compound reached a concentration of 26 ng/g in the frontal
cortex (p < 0.0001) and 40 ng/g in the hippocampus
(p < 0.01), whereas in any of these brain structures the pres-
ence of BP-1 was found (Fig. 2d, e). In the control group, the
BP-3 level in the hippocampus was above the detection limit
in only one female, while it was not in the frontal cortex and
liver.
Total Antioxidant Activity and Lipid Peroxidation
in Brain Structures of Female Rats Exposed to BP-3
It has been found that BP-3 did not change the antioxidant
activity of hippocampal tissue samples (p = 0.1195), while to a
small extent yet significantly it decreased this parameter in
frontal cortex (p < 0.05) (Fig. 3a). However, the tested com-
pound significantly and relatively strongly increased lipid per-
oxidation in the hippocampus (p < 0.01) and, especially, in the
frontal cortex (p = 0.01) (Fig. 3b).
The Effect of BP-3 on the Extracellular Glutamate
Concentrations and Expression of Main Glutamate
Transporters in the Hippocampus and Frontal Cortex
The extracellular glutamate concentration in the control ani-
mals was higher in the frontal cortex (p < 0.001) than in the
hippocampus (p < 0.01) (Fig. 4a, b). Exposure to BP-3 in-
creased the level of this neurotransmitter by 7.5-fold in the
hippocampus and by 5.8-fold in the frontal cortex.
Determining the expression of the mRNA and protein levels
of the two major glutamate transporters illustrated that BP-3
significantly decreased GLT-1 mRNA (frontal cortex p < 0.05,
hippocampus p < 0.01) and increased xc-mRNA (frontal cortex
p < 0.05, hippocampus p < 0.05) in both of the examined brain
structures, although changes in mRNA did not correlate with
the protein levels (Fig. 4c–f). In the frontal cortex, BP-3 had no
effect on GLT-1 (p = 0.4568) and xc- (p = 0.3633) transporters,
while in the hippocampus the GLT-1 protein level also did not
change (p = 0.4222), but significantly and strongly increased
the xc- transporter (p < 0.05).
The Effect of BP-3 on Estrogen and Progesterone
Receptors’ Expression in the Hippocampus
and Frontal Cortex
In the frontal cortex, mRNA coding of all three types of ER,
i.e., ERα, ERβ, and GPR-30, was significantly reduced
Fig. 3 Effects of BP-3 exposure on antioxidant capacity in the frontal
cortex and hippocampus (a) and lipid peroxidation levels in these brain
structures (b) (n = 8). The data were recalculated and expressed as a
percent of the control ± S.E.M, where 100% is the basal antioxidant
capacity and lipid peroxidation in control animals. *p < 0.05, **p < 0.01
vs control group. BP-3—benzophenone-3; C—control group
Fig. 4 Effects of BP-3 dermal administration on the concentration of Glu
in the extracellular space in the frontal cortex (a) and hippocampus (b), on
the mRNA expression of the Glu transporters GLT-1 (c) and xCT (d) and
protein levels of GLT-1 (e) and xCT (f) in the frontal cortex and hippo-
campus (n = 7). All the values are shown as the means ± S.E.M.
*p < 0.05, **p < 0.01, ***p < 0.001 vs control group. aCSF—artificial
cerebrospinal fluid; BP-3—benzophenone-3; C—control group. At the
bottom representative immunoblots showing the expression of GLT-1 and
xCT in the frontal cortex and hippocampus with reference to the total
protein concentration loaded on the gel were shown
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(p < 0.05, p < 0.05, p < 0.01, respectively) in the female rats
exposed to BP-3 (Fig. 5a–e). In the hippocampus, there were
no differences in the mRNA of ERα (p = 0.1161) and GPR-30
(p = 0.5084) receptors, while mRNA ERβ was significantly
higher in BP-3-treated rats than in the control animals
(p < 0.001) (Fig. 5b–f). At the protein level, there were no
significant differences in the levels of ERα assayed in both
the cytosolic and nuclear fraction, in the nuclear ERβ concen-
tration, and in the membrane GPR-30 receptor in the frontal
cortex and hippocampus between animals receiving BP-3 and
controls (Table 2). The PR concentration did not change in the
frontal cortex, while BP-3 reduced its level in the cytosol
fraction of the hippocampus.
The Effect of BP-3 on the Expression of AhR in Brain
Structures of Female Rats
In the frontal cortex, BP-3 had no effect on the AhR
expression on both the mRNA (p = 0.3323) and protein
(p = 0.9853) level (Fig. 6a, c), although in the hippocam-
pus of BP-3-treated animals a significant increase in
Fig. 5 Effects of BP-3 exposure
on the mRNA expression of the
estrogen receptors: ERα (a, b),
ERβ (c, d) and GPR-30 (e, f) in
the frontal cortex and hippocam-
pus (n = 8). All the values are
shown as the means ± S.E.M.
*p < 0.05, **p < 0.01,
***p < 0.001 vs control group.
BP-3—benzophenone-3; C—
control group
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mRNA expression (p < 0.01) and a decrease in the pro-
tein (p < 0.05) level of AhR were observed (Fig. 6b, d).
Lack of BP-3 Effect on Apoptotic Markers
in the Hippocampus and Frontal Cortex
It has been shown that BP-3 had no effect on the concentration
of the active form of caspase-3, the executive enzyme in the
apoptotic process, as well as on the key enzymes in the intra-
cellular (caspase-9) and receptors’ (caspase-8) apoptotic path-
way in the hippocampus and frontal cortex (Table 3). Also, the
test compound did not change the level of the main pro-
apoptotic (Bax) and anti-apoptotic (Bcl-2) proteins in both
of the examined brain structures.
The lack of BP-3 influence on caspase-3 activation has also
been confirmed by immunofluorescence studies, in which a
similar expression of the active form of this enzyme in neu-
rons (labeled with MAP-2) was demonstrated in the frontal
cortex (p = 0.8921) and CA1 (p = 0.6693), CA3 (p = 0.1475),
and dentate gyrus (DG) (p = 0.1123) regions of the hippocam-
pus in control and BP-3 treated animals (Fig. 7).
Lack of BP-3 Effect on Microglia Activation
Exposure of animals to BP-3 had no effect on mRNA
expression of selected markers of microglia cells’ activa-
tion, i.e., Aif, a microglia/macrophage-specific calcium-
binding protein, Cd40, a costimulatory receptor occurring
on the antigen-presenting cells, and C1q, a initiating pro-
tein in the classical pathway of complement activation
(data not shown). Also, the Iba1 factor determined in the
hippocampus and frontal cortex at the protein level was at
a similar concentration in control and BP-3-treated ani-
mals (data not shown).
Lack of BP-3 Effect on Caspase-1, RIP-1 Protein
and GPx in the Hippocampus
Because there was no activation of apoptosis in the hippocam-
pus and frontal cortex of animals exposed to BP-3, yet an
increase in the glutamate level and lipid peroxidation were
observed, selected markers of regulated necrosis, i.e.,
necroptosis and pyroptosis, were therefore determined in the
hippocampus, a structure more vulnerable to damage than the
frontal cortex. However, it was found that BP-3 had no effect
on the caspase-1 (p = 0.7074) and RIP-1 (p = 0.1277) protein
level, as well as on the expression and activation of glutathi-
one peroxidase (p = 0.8924, p = 0.8358, respectively) in this
structure (Fig. 8a–d).
The Effect of BP-3 on the Sex and Thyroid Hormones
Plasma Concentration
Exposure of female rats to BP-3 during the prenatal period
and, next, for 2 weeks into adulthood had no significant effect
on the blood 17β-estradiol (p = 0.4871), testosterone (p =
0.3840), and prolactin (p = 0.7139) levels, but significantly
decreased the concentration of progesterone (p < 0.05)
(Fig. 9a–d).
Statistically significant higher levels of a free, unbound,
active form of thyroid hormones, both fT3 (p < 0.05) and
fT4 (p < 0.01), were found in the blood of female rats admin-
istered BP-3 (Fig. 10b, c). The hyperthyroidism induced by
BP-3 was also confirmed by significantly lower TSH concen-
tration in animals receiving this compound than in control
animals (p < 0.01) (Fig. 10a).
The Effect of BP-3 on the Hematological Parameters
It has been found that BP-3 decreased the red blood cell
(RBC) count (p < 0.001), hemoglobin concentration (HGB)
Table 2 Effects of BP-3 dermal
administration to female rats on
the level of estrogen (ERα, ERβ,
and GRP30) and progesterone
receptors (PR) in the frontal cor-
tex and hippocampus
Protein Fraction Brain structure C BP-3 p
ERα Cytosol Frontal cortex 100.0 ± 3639 96.50 ± 11.62 0.7938
Hippocampus 100.0 ± 22.74 122.0 ± 30.48 0.5734
Nucleus Frontal cortex 100.0 ± 25.61 101.6 ± 34.16 0.9708
Hippocampus 100.0 ± 27.02 75.04 ± 17.06 0.4529
ERβ Nucleus Frontal cortex 100.0 ± 13.27 101.4 ± 7260 0.9285
Hippocampus 100.0 ± 8386 102.3 ± 7092 0.8401
GPR30 Membrane Frontal cortex 100.0 ± 9807 113.5 ± 9224 0.3362
Hippocampus 100.0 ± 7361 108.0 ± 6389 0.4253
PR Cytosol Frontal cortex 100.0 ± 6363 94.44 ± 5378 0.5175
Hippocampus 100.0 ± 7013 79.74 ± 3992 0.0355
Nucleus Frontal cortex 100.0 ± 6032 114.1 ± 11.24 0.2918
Hippocampus 100.0 ± 16.60 95.10 ± 8147 0.8066
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(p < 0.001), hematocrit (HCT) (p < 0.001), and corpuscular
hemoglobin concentration (MCH) (p < 0.05), and increased
the platelet count (PLT) (p < 0.05), but had no effect on the
leukocyte count (WBC) (p = 0.8792), with the mean corpus-
cular volume (MCV) (p = 0.1169) and mean cell hemoglobin
concentration (MCHC) (p = 0.6108) (Fig. 11).
Discussion
Current studies have shown that after the same exposure to
BP-3, this compound was present in the blood of females at a
lower concentration than that observed in our previous studies
in males (Pomierny et al. 2019). This is consistent with data
showing that after dermal application of BP-3, its maximum
plasma and urine concentrations in humans are higher in men
than in women (Janjua et al. 2008). Moreover, in the present
study, the blood BP-3 level in female rats was similar to that
observed in humans after 4 days of whole-body topical appli-
cation of 2 mg/cm2 of a sunscreen formula containing 10%
BP-3 (Janjua et al. 2008). Also, the level of BP-3 in the liver in
female rats was significantly lower than that previously ob-
served in males, while the levels of its main metabolite, BP-1,
were comparable. The liver is the main organ for BP-3 bio-
transformation (Kim and Choi 2014; Okereke et al. 1993) and
the higher ratio of the metabolite to the parent compound
observed in this tissue in female rats, rather than males, indi-
cated that females probably metabolize this compound faster.
Some data show that BP-3 not only is easily absorbed
through the skin but also passes through the blood-brain bar-
rier (Krzyżanowska et al. 2018;Wnuk et al. 2018b). However,
the key issue is whether this compound can achieve sufficient
concentration in the brain structures to affect the function or
reduce the survival of nerve cells. Neurodegenerative effects
of BP-3 have been relatively well demonstrated in vitro
(Broniowska et al. 2016; Wnuk et al. 2018a), but in vivo only
after prenatal exposure of mice to this compound (Wnuk et al.
2018b, 2019), and in male rats after combined prenatal and
adult exposure (Pomierny et al. 2019). In the BP-3 exposure
model we used, the BP-3 concentration in the frontal cortex
and hippocampus of male rats was about 50 ng/g, while in the
hippocampus of female rats it was about 40 ng/ml, although in
Fig. 6 Effects of BP-3 exposure on the mRNA expression of AhR in the
frontal cortex (a) and hippocampus (b) and on the protein level of AhR in
the frontal cortex (c) and hippocampus (d) (n = 8). All the values are
shown as the means ± S.E.M. **p < 0.01 vs control group. BP-3—
benzophenone-3; C—control group. Representative immunoblots show-
ing the expression of AhR in the frontal cortex (c) and hippocampus (d)
with reference to the total protein concentration loaded on the gel were
shown
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the frontal cortex it was only 26 ng/ml. A higher concentration
of BP-3 in the hippocampus than in the frontal cortex of fe-
male rats may be the cause of a greater increase of lipid per-
oxidation, which is an important marker of free radical action
on the membrane polyunsaturated fatty acids observed in this
structure.
The neurotoxic effect of some xenobiotics result from
changes in the brain expression of estrogen receptors, espe-
cially a decrease in nuclear ERβ and membrane GPR30 and,
in consequence, inhibition of estrogen’s neuroprotective ac-
tion (Lan et al. 2014; Lebesgue et al. 2009; Lee et al. 2012;
Zhang et al., 2018). In the present study, a decrease in the
mRNA level of all ER subtypes in the frontal cortex was
observed, but there were no changes at the protein level either
in the frontal cortex or in the hippocampus. Moreover, the
17β-estradiol blood concentration also did not change in the
female rats exposed to BP-3. In contrast to results obtained in
female rats, we previously observed a decrease in nuclear
ERβ and membrane GPR30 levels in the hippocampus and
frontal cortex, and ERα in the hippocampus of male rats, thus
indicating gender-dependent BP-3 action. The lack of the BP-
3 effect on ER expression in female rats may result from
differences in the concentration of this compound in the brain
or from various ER expressions in female and male rats.
In contrast to the lack of the BP-3 effect on the ER level in
the brain of female rats, the effect of this compound on the
concentration of extracellular glutamate in the hippocampus
and frontal cortex in females was similar to that of the previ-
ously observed males. Moreover, despite a significantly
higher BP-3 concentration in the hippocampus than in the
frontal cortex in both of the studied brain structures, BP-3 with
a similar potency increased the extracellular glutamate level.
Enhanced release of glutamate and, in consequence, excessive
stimulation of NMDA receptors and an increase in intracellu-
lar Ca2+ is considered to be the most important cause of neu-
ronal degeneration (Brassai et al. 2015; Lau and Tymianski
2010). The concentration of glutamate in the synapse is main-
ly regulated by the uptake of this neurotransmitter into glial
cells, primarily into astrocytes, by the plasma membrane GLT-
1 transporter. BP-3 decreased mRNA coding GLT-1 in the
hippocampus and frontal cortex, although this change did
not translate to the GLT-1 protein level. However, the second
essential transporter in regulating the extracellular glutamate
level, xCT, could be responsible for the increased level of this
neurotransmitter in the hippocampus. xCT is a cystine/
glutamate antiporter which exchanges extracellular cysteine
for intracellular glutamate, and consequently, it increases the
level of extracellular glutamate (Massie et al. 2015). We found
that BP-3 increased the mRNA of this transporter in both brain
structures studied, and strongly raised the level of xCT protein
in the hippocampus, yet had no effect on its concentration in
the frontal cortex. Thus, unlike in males, in females the in-
crease in extracellular glutamate concentration correlates well
only with changes in xCT, yet not GLT-1, and only in the
hippocampus. The cause of the effect of BP-3 on the level of
glutamate in the frontal cortex of female rats is difficult to
explain, because it was not due to changes in the examined
glutamate transporters or, indeed, also not connected with
microglial activation, since this compound did not increase
the expression of the tested microglia markers.
The obtained results also indicate that, although BP-3 in-
creased glutamate levels and intensified lipid peroxidation in
both brain structures, it did not induce the process of apopto-
sis. This was an unexpected result as enhanced lipid peroxi-
dation, one of the effects of free radical action on membrane
polyunsaturated fatty acids, argued that BP-3 induced oxida-
tive stress, which has often evoked the intracellular pathway
of apoptosis. The brain, due to weak antioxidant activity and
strong production of free radicals during mitochondrial respi-
ration, and the metabolism of some neurotransmitters, mainly
dopamine, is particularly sensitive to oxidative stress-induced
damage. We have previously observed changes in apoptosis
markers in males exposed to BP-3 in the frontal cortex, where-
as in the hippocampus, increased caspase-3 activity had only
been demonstrated in the CA1 region by fluorescent staining,
yet not when determined by Western blotting (Pomierny et al.
Table 3 Effects of BP-3 dermal
administration to female rats on
selected markers of apoptosis in
the frontal cortex and
hippocampus
Protein Fraction Brain structure C BP-3 p
Caspase-3 active Cytosol Frontal cortex 100.0 ± 12.31 100.9 ± 16.78 0.9664
Hippocampus 100.0 ± 24.43 113.8 ± 21.06 0.6852
Caspase-8
active
Cytosol Frontal cortex 100.0 ± 26.32 123.7 ± 63.00 0.7358
Hippocampus 100.0 ± 23.34 87.81 ± 22.88 0.7156
Caspase-9 Cytosol Frontal cortex 100.0 ± 6028 116.3 ± 5682 0.0731
Hippocampus 100.0 ± 12.95 107.5 ± 12.51 0.6861
Bax Cytosol Frontal cortex 100.0 ± 11.18 104.9 ± 20.35 0.8379
Hippocampus 100.0 ± 22.77 75.53 ± 14.40 0.3817
Bcl-2 Membrane Frontal cortex 100.0 ± 10.19 104.9 ± 16.79 0.8077
Hippocampus 100.0 ± 11.87 121.7 ± 22.84 0.4147
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2019). The lack of signals for the induction of apoptosis in
females may have resulted from a lower BP-3 concentration in
the brain of females, especially in the frontal cortex, than in
males, which has not yet led to the death of neurons. However,
it cannot be ruled out that BP-3 induced the death of neurons
by other means than apoptosis, such as necroptosis, pyroptosis
or ferroptosis, which are types of programmed necrosis, which
occurs without chromatin condensation and caspase-3, 8, and
Fig. 7 Effects of BP-3 on the relative expression of the active form of
caspase-3 in neurons of the frontal cortex (a), the CA1 region of the
hippocampus (b), the CA3 region of the hippocampus (c) and the dentate
gyrus (DG) of the hippocampus (d) (n = 4). The red (TexasRed) fluores-
cence data are expressed as the relative fluorescence unit (RFU) ± S.E.M.
Representative microphotographs for the frontal cortex and the CA1,
CA3, and DG regions of the hippocampus have been placed. Caspase-3
(TexasRed, red), MAP2 (FITC, green), and nucleus (DAPI, blue) staining
of 20-μm-thick brain sections of control animals and animals exposed to
BP-3. Scalebar = 75 μm
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9 activation. This possibility was studied in the hippocampus,
because in this structure the concentration of BP-3 was about
60% higher than in the frontal cortex, and in this tissue lipid
peroxidation was also more severe. The lack of changes in the
level of the active form of caspase-1 and expression of
threonine-serine kinase—RIP1, markers of pyroptosis and
necroptosis, respectively revealed that induction of these pro-
cesses by BP-3 was rather unlikely (Chen et al. 2016).
Likewise, no reduction in glutathione peroxidase expression
and activity in the hippocampus suggested that BP-3 also did
not induce the ferroptosis process (Xie et al. 2016).
The results obtained suggest that the adverse changes
observed in the female rats exposed to BP-3, like the
enhanced glutamate level and increased lipid peroxida-
tion, did not lead to cell death. Despite the lack of apo-
ptosis, the fact that BP-3 disturbed memory processes in-
dicates its unfavorable effect on brain function. Indeed,
we found that BP-3 did not affect short-term memory, as
determined in the NOR test, but significantly inhibited
spatial memory assayed by the NOL test. Since the pe-
ripheral cortex is mainly involved in the performance of
the NOR test, while the hippocampus participates in the
NOL test, this confirmed the biochemical results that BP-
3 more strongly affects the hippocampus than the frontal
cortex in female rats.
In contrast to the weaker effects of the BP-3 on females
than male brains, this compound more strongly affected the
endocrine system in female rats and evoked disturbance in
hematological parameters. As demonstrated in the current
studies, the higher levels of free, unbound, and active forms
of thyroid hormones, both fT3 and fT4, while reducing TSH
concentration, indicated that BP-3 caused hyperthyroidism.
Most of the existing data indicates that the benzophenones
rather reduce the level of thyroid hormones. For example, in
epidemiological studies an association between urinary BP-3
concentrations and decreases in thyroid hormones in the gen-
eral population was demonstrated (Kim et al. 2017). However,
in pregnant women a positive association between serum con-
centrations of 4-hydroxy-benzophenone and T3 and T4 levels
was observed, and previously we found that benzophenone-2
administered dermally to adult male rats also evoked hyper-
thyroidism (Broniowska et al. 2018; Krause et al. 2018).
Increased thyroid hormone levels, which in our BP-3 admin-
istration model occur only in females yet not in males, in
Fig. 8 Effects of BP-3 exposure on the protein expression of active form
of caspase-1 (a), threonine-serine kinase RIP-1 (b), glutathione peroxi-
dase (c), and activity of GPx (d) in the hippocampus (n = 7). All the
values are shown as the means ± S.E.M. RIP-1—threonine-serine kinase
RIP-1; GPx—glutathione peroxidase; BP-3—benzophenone-3; C—
control group. Representative immunoblots showing the expression of
caspase-1, RIP1, and GPx in the hippocampus with reference to the total
protein concentration loaded on the gel were shown
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addition to the potential, adverse metabolic effects, may also
be one of the causes of smaller changes observed in the brain
of female rather than male rats through its exertion of neuro-
protective effects. These hormones cross the blood-brain bar-
rier and current data indicate that their central action occurs
not only in the developmental period, but also in adults and
that they exert a neuroprotective effect (Remaud et al. 2014;
Vallortigara et al. 2009).
Another important effect of BP-3 in females was a strong
decrease in blood progesterone levels. No change in 17β-
estradiol levels and a decrease in progesterone production indi-
cated that BP-3 mainly disturbed the function of the corpus
luteum and not the ovarian follicles. However, BP-3 are known
to exert the agonistic effect of ER and possibly also antagonistic
on PR, so all these effects can contribute to a weakening of
fertility (Schlumpf et al. 2004; Schreurs et al. 2005).
Fig. 9 Effects of BP-3 exposure
on 17β-estradiol (a), progester-
one (b), testosterone (c), and pro-
lactin (d) plasma level (n = 7). All
data are expressed as the means
±SEM. *p < 0.05 vs control
group. BP-3—benzophenone-3;
C—control group
Fig. 10 Effects of BP-3 adminis-
tration on TSH (a), fT3 (b), and
fT4 (c) plasma concentration (n =
7). All data are expressed as the
means ± SEM. TSH—thyroid-
stimulating hormone; fT3—free
fractions of triiodothyronine;
fT4—free fractions of thyroxin;
*p < 0.05, **p < 0.01 vs control
group. BP-3—benzophenone-3;
C—control group
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The present study also showed that BP-3 administration
decreased the number of erythrocytes and hemoglobin con-
centration, but increased the platelet count. These were ad-
verse effects, which suggested that BP-3 may affect the bone
marrow, leading to anemia with an increase in platelets or act
directly, damaging erythrocytes. The effect of BP-3 on hema-
tological parameters has not been studied so far, but it was
demonstrated that the plant benzophenone, garcinol, induced
apoptosis of human erythrocytes in in vitro conditions (Fazio
et al., 2015).Thus, it is possible that the reduction in erythro-
cytes shown in the present study was also due to the direct
effect of BP-3 on red cells.
Conclusion
In summary, the presented data indicated that after the same
exposure to BP-3, in female rats, concentration of this com-
pound in blood and in the brain was lower than previously
observed in male rats. Moreover, in contrast to male rats in the
frontal cortex and hippocampus of female rats’ apoptosis pro-
cesses were not induced, despite that increase in extracellular
glutamate concentration, enhanced lipid peroxidation, and in-
hibition in spatial memory were observed. However, this com-
pound in female more strongly than in male rats affected the
endocrine system and evoked a disturbance in the hematolog-
ical parameters.
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Fig. 11 The effect of benzophenone-3 administration on hematological
parameters in female rat blood (n = 12). All data are expressed as the
means ± SEM. WBC—leukocyte count; RBC—red blood cell count;
PLT—platelet count; HGB—hemoglobin concentration; HCT—
hematocrit; MCV—mean corpuscular volume; MCH—mean cell hemo-
globin; MCHC—mean cell hemoglobin concentration; BP-3—benzo-
phenone-3; C—control group
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